After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
Eli Lilly partnership aims to identify new treatments for ALS based on antibodies from people with very slow disease ...
Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that primarily affects the motor system, resulting in progressive muscle weakness and — ultimately — death. The disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback